Natera, Inc. is a clinical genetic testing company based in Austin, Texas that specializes in non-invasive, cell-free DNA (cfDNA) testing technology, with a focus on women's health, cancer, and organ health. Natera's proprietary technology combines novel molecular biology techniques with a suite of bioinformatics software that allows detection down to a single molecule in a tube of blood. Natera operates CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California and Austin, Texas.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| NTRA | Natera, Inc. | 2026-10-08 08:48:30 | 387.1 | -8.1 | -2.05 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NTRA | 0001604821 | Natera, Inc. | US6323071042 | 529900CQ3OZ0A0VYVU59 | 010894487 | Nasdaq | 8071 | Services-Medical Laboratories | 1231 | DE | 13011 MCCALLEN PASS | AUSTIN | TX | 78753 | UNITED STATES | US | 650-249-9090 | 13011 MCCALLEN PASS, AUSTIN, TX, 78753 | 13011 MCCALLEN PASS, AUSTIN, TX, 78753 | Natera, Inc. | Genetic testing | 2004 | Steve Chapman | 3,018 | https://natera.com | 21,830,000,000 | 143,612,000 | 144,144,170 | Natera, Inc. is a clinical genetic testing company based in Austin, Texas that specializes in non-invasive, cell-free DNA (cfDNA) testing technology, with a focus on women's health, cancer, and organ health. Natera's proprietary technology combines novel molecular biology techniques with a suite of bioinformatics software that allows detection down to a single molecule in a tube of blood. Natera operates CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California and Austin, Texas. | 2026-10-01 18:15:54 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 21,830,000,000 | 8,680,000,000 | 66.0076 | 141,731,250 | 6,545,066 | 4.8415 |
| 2024 | 13,150,000,000 | 7,890,000,000 | 150 | 135,186,184 | 14,428,307 | 11.9481 |
| 2023 | 5,260,000,000 | 2,690,000,000 | 104.6693 | 120,757,877 | 7,472,202 | 6.5959 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| John Fesko | President, Chief Business Officer | 2025 | 504,652 | — | 4,186,634 | 351,604 | 9,900 | 5,052,790 |
| Solomon Moshkevich | President | 2025 | 504,652 | — | 4,500,844 | 351,604 | 9,900 | 5,367,000 |
| Steven Chapman | Chief Executive Officer, President | 2025 | 853,710 | — | 12,979,558 | 1,114,151 | 9,900 | 14,957,319 |
| Michael Brophy | Chief Financial Officer | 2025 | 562,794 | — | 4,500,844 | 390,175 | 6,209 | 5,460,022 |
| Matthew Rabinowitz | Executive Chairman | 2025 | 426,434 | — | 10,383,434 | 473,514 | 0 | 11,283,382 |
| Fiscal Year | Employee Count |
|---|---|
| 2020 | 1,815 |
| 2019 | 1,039 |
| 2018 | 975 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 2,306,113,000 | 1,696,911,000 | 1,082,571,000 |
| Cost Of Revenue | — | — | — |
| Gross Profit | 2,306,113,000 | 1,696,911,000 | 1,082,571,000 |
| Research And Development Expenses | 624,110,000 | 404,138,000 | 320,678,000 |
| General And Administrative Expenses | 1,177,261,000 | 841,314,000 | 618,307,000 |
| Operating Expenses | 2,616,024,000 | 1,919,205,000 | 1,528,816,000 |
| Operating Income | -309,911,000 | -222,294,000 | -446,245,000 |
| Net Income | -208,160,000 | -190,426,000 | -434,801,000 |
| Earnings Per Share Basic | -1.52 | -1.53 | -3.78 |
| Earnings Per Share Diluted | -1.52 | -1.53 | -3.78 |
| Weighted Average Shares Outstanding Basic | 136,721,000 | 124,718,000 | 114,997,000 |
| Weighted Average Shares Outstanding Diluted | 136,721,000 | 124,718,000 | 114,997,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 1,076,140,000 | 945,587,000 | 642,095,000 |
| Marketable Securities Current | — | 22,689,000 | 236,882,000 |
| Accounts Receivable | 296,528,000 | 314,165,000 | 278,289,000 |
| Inventories | 68,443,000 | 44,744,000 | 40,759,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 55,828,000 | 48,635,000 | 60,524,000 |
| Total Assets Current | 1,496,939,000 | 1,375,820,000 | 1,258,549,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 241,184,000 | 162,046,000 | 111,210,000 |
| Other Assets Non Current | 36,897,000 | 36,720,000 | 15,403,000 |
| Total Assets Non Current | 901,405,000 | 284,915,000 | 183,150,000 |
| Total Assets | 2,398,344,000 | 1,660,735,000 | 1,441,699,000 |
| Accounts Payable | 33,156,000 | 34,922,000 | 14,998,000 |
| Deferred Revenue | 24,907,000 | 19,754,000 | 16,612,000 |
| Short Term Debt | 80,323,000 | 80,362,000 | 80,402,000 |
| Other Liabilities Current | 188,659,000 | 146,893,000 | 149,405,000 |
| Total Liabilities Current | 441,228,000 | 344,045,000 | 307,274,000 |
| Long Term Debt | — | — | 282,945,000 |
| Other Liabilities Non Current | 11,687,000 | — | — |
| Total Liabilities Non Current | 244,703,000 | 121,270,000 | 369,098,000 |
| Total Liabilities | 685,931,000 | 465,315,000 | 676,372,000 |
| Common Stock | 14,000 | 12,000 | 11,000 |
| Retained Earnings | -2,776,022,000 | -2,567,862,000 | -2,377,436,000 |
| Accumulated Other Comprehensive Income | -258,000 | -344,000 | -3,085,000 |
| Total Shareholders Equity | 1,712,413,000 | 1,195,420,000 | 765,327,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 41,764,000 | 30,968,000 | 24,097,000 |
| Share Based Compensation Expense | 354,404,000 | 274,428,000 | 191,808,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | -20,752,000 | 35,876,000 | 33,904,000 |
| Change In Inventories | 20,871,000 | 3,985,000 | 5,353,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | 8,634,000 | -10,807,000 | 26,072,000 |
| Change In Accounts Payable | 753,000 | 13,210,000 | -15,458,000 |
| Change In Other Liabilities | 60,269,000 | 40,328,000 | 21,619,000 |
| Cash From Operating Activities | 215,301,000 | 135,664,000 | -246,955,000 |
| Purchases Of Marketable Securities | — | 122,010,000 | 98,303,000 |
| Sales Of Marketable Securities | 23,000,000 | 24,822,000 | 306,000,000 |
| Acquisition Of Property Plant And Equipment | 106,188,000 | 66,423,000 | 39,199,000 |
| Acquisition Of Business | 16,021,000 | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -132,209,000 | 137,624,000 | 168,498,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 25,037,000 | 12,988,000 | 235,441,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 47,461,000 | 30,204,000 | 254,461,000 |
| Change In Cash | 130,553,000 | 303,492,000 | 176,004,000 |
| Cash At End Of Period | 1,076,140,000 | 945,587,000 | 642,095,000 |
| Income Taxes Paid | 499,000 | 1,307,000 | 295,000 |
| Interest Paid | 4,069,000 | 7,897,000 | 11,346,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -1.52 | -1.53 | -3.78 |
| Price To Earnings Ratio | -150.7171 | -103.4641 | -16.5714 |
| Earnings Growth Rate | -0.6536 | -59.5238 | -32.1364 |
| Price Earnings To Growth Ratio | 230.5972 | 1.7382 | 0.5157 |
| Book Value Per Share | 12.5249 | 9.585 | 6.6552 |
| Price To Book Ratio | 18.2908 | 16.5154 | 9.4122 |
| Ebitda | -161,828,000 | -147,466,000 | -397,771,000 |
| Enterprise Value | — | — | 6,924,664,080 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | 0.4748 |
| Capital Expenditures | 120,902,000 | 81,804,000 | 42,854,000 |
| Free Cash Flow | 94,399,000 | 53,860,000 | -289,809,000 |
| Return On Equity | -0.1216 | -0.1593 | -0.5681 |
| One Year Beta | 1.1853 | 1.5412 | 1.1247 |
| Three Year Beta | 1.2472 | 1.5276 | 1.5861 |
| Five Year Beta | 1.4783 | 1.3693 | 1.3865 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Brophy Michael Burkes | Chief Financial Officer | 2029-06-23 | 12,500 | D | 37,500 |
| Brophy Michael Burkes | Chief Financial Officer | 2029-06-08 | 25,000 | D | 50,000 |
| Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS | 2026-10-01 | 200 | D | 109,714 |
| Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS | 2026-10-01 | 954 | D | 108,760 |
| Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS | 2026-10-01 | 1,846 | D | 106,914 |
| Name Of Reporting Person | Type Of Reporting Person | Report Date | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| William F Hagerty, IV | Senator | 2021-05-04 | Sale (Partial) | 2021-04-20 | Self | $1,001 - $15,000 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Josh Gottheimer | 2025-10-15 | NJ05 | Purchase | 2025-09-22 | Joint | $1,001 - $15,000 |
| Josh Gottheimer | 2025-09-05 | NJ05 | Purchase | 2025-08-22 | Joint | $1,001 - $15,000 |
| Josh Gottheimer | 2025-08-11 | NJ05 | Sale (Partial) | 2025-07-22 | Joint | $1,001 - $15,000 |
| Josh Gottheimer | 2024-12-05 | NJ05 | Purchase | 2024-11-20 | Joint | $1,001 - $15,000 |
| Daniel Goldman | 2023-05-19 | NY10 | Sale (Partial) | 2023-04-10 | — | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Apella Capital, LLC | 2026-09-30 | 300,230 | 759 | 395.5599 |
| Artemis Investment Management LLP | 2026-09-30 | 83,212,942 | 201,333 | 413.31 |
| HWG Holdings LP | 2026-09-30 | 9,825,205 | 23,772 | 413.31 |
| Vann Equity Management LLC | 2026-09-30 | 416,616 | 1,008 | 413.3095 |
| Wealth Enhancement Trust Services, Inc. | 2026-09-30 | 352,553 | 853 | 413.3095 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| VANGUARD EXPLORER FUND | 2026-07-31 | Investor Shares | VEXPX | 242,967 | 65,056,843.92 | 0.2941 |
| EA Series Trust | 2026-07-31 | JLens 500 Jewish Advocacy U.S. ETF | TOV | 479 | 128,257.04 | 0.05 |
| EA Series Trust | 2026-07-31 | Manzil Russell Halal USA Broad Market ETF | MNZL | 110 | 29,453.6 | 0.12 |
| Tidal Trust III | 2026-07-31 | Fundstrat Granny Shots US Small- & Mid-Cap ETF | GRNJ | 45,200 | 12,102,752 | 2.3891 |
| COLUMBIA FUNDS SERIES TRUST I | 2026-07-31 | Multi-Manager Directional Alternative Strategies Fund Institutional Class | CDAZX | 19,871 | 5,320,658.96 | 1.6226 |